NYSE - Nasdaq Real Time Price USD

Zoetis Inc. (ZTS)

Compare
180.92 +4.11 (+2.32%)
As of 12:14 PM EST. Market Open.
Loading Chart for ZTS
DELL
  • Previous Close 176.81
  • Open 176.71
  • Bid 179.95 x 1300
  • Ask 180.12 x 800
  • Day's Range 176.62 - 181.04
  • 52 Week Range 144.80 - 201.92
  • Volume 771,102
  • Avg. Volume 2,201,736
  • Market Cap (intraday) 81.625B
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) 34.01
  • EPS (TTM) 5.32
  • Earnings Date Feb 11, 2025 - Feb 17, 2025
  • Forward Dividend & Yield 1.73 (0.98%)
  • Ex-Dividend Date Oct 31, 2024
  • 1y Target Est 214.80

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

www.zoetis.com

14,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZTS

View More

Performance Overview: ZTS

Trailing total returns as of 12/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ZTS
7.43%
S&P 500
26.59%

1-Year Return

ZTS
2.00%
S&P 500
31.42%

3-Year Return

ZTS
16.78%
S&P 500
31.92%

5-Year Return

ZTS
56.64%
S&P 500
93.91%

Compare To: ZTS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZTS

View More

Valuation Measures

Annual
As of 12/2/2024
  • Market Cap

    79.77B

  • Enterprise Value

    84.82B

  • Trailing P/E

    33.23

  • Forward P/E

    27.32

  • PEG Ratio (5yr expected)

    2.46

  • Price/Sales (ttm)

    8.83

  • Price/Book (mrq)

    15.24

  • Enterprise Value/Revenue

    9.27

  • Enterprise Value/EBITDA

    22.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.55%

  • Return on Assets (ttm)

    14.66%

  • Return on Equity (ttm)

    47.30%

  • Revenue (ttm)

    9.15B

  • Net Income Avi to Common (ttm)

    2.43B

  • Diluted EPS (ttm)

    5.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.71B

  • Total Debt/Equity (mrq)

    129.44%

  • Levered Free Cash Flow (ttm)

    1.87B

Research Analysis: ZTS

View More

Company Insights: ZTS

Research Reports: ZTS

View More

People Also Watch